Clinical trials: sponsored by Bayer
Lymphoma
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
Primary Objectives: 1. To determine the efficacy of in vivo purging achieved by rituximab in the two groups. 2. To determine the number of apheresis procedures, total stem cell yield/kg patient body weight and the toxicity…
- Trial name
- NCT00499343
- Testing
- Etoposide, G-CSF, GM-CSF
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
The primary objective of this study is to compare the effectiveness of a dose-escalation regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib given in patients with metastatic RCC.
- Trial name
- NCT00557830
- Testing
- Sorafenib Escalated Dose, Sorafenib Standard Dose
- Where
- 13 sites in United States
- Volunteers
- 12 people
- Sponsor
- Accelerated Community Oncology Research Network
Hemophilia A
BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
A study to assess treatment with a new formulation of recombinant factor VIII reconstituted with liposomes (BAY79-4980) to evaluate whether a once-a-week treatment is safe and can prevent bleeds in subjects with severe…
- Trial name
- NCT00623727
- Testing
- rFVIII-FS/pegylated liposomes (BAY79-4980), rFVIII-FS/WFI (BAY14-2222)
- Where
- 95 sites in United States, Argentina and 24 more
- Volunteers
- 143 people
- Sponsor
- Bayer
Recurrent Glioblastoma Multiforme
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
PURPOSE AND OBJECTIVES: Primary Objective To evaluate the activity of Sorafenib plus protracted, daily temozolomide in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month PFS.
- Trial name
- NCT00597493
- Testing
- Sorafenib and Temozolomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Macular Degeneration
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
Rollover study for subjects in prior VEGF Trap-Eye Phase I and II studies. Primary objective is to assess long-term safety and tolerability of continuing intravitreal treatment in subjects with wet age-related macular…
- Trial name
- NCT00527423
- Testing
- VEGF Trap Eye
- Where
- 33 sites in United States
- Volunteers
- 157 people
- Sponsor
- Regeneron Pharmaceuticals
Hand-foot Skin Reaction, Rash
Sorafenib-induced Hand- Foot Skin Reaction Treatment
The purpose of this study is to evaluate treatments for a rash caused by sorafenib.
- Trial name
- NCT00667589
- Testing
- urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Macular Edema Secondary to Central Retinal Vein Occlusion
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
This is a phase 3 study to determine the efficacy of VEGF Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.
- Trial name
- NCT00943072
- Testing
- VEGF Trap-Eye 2.0mg
- Where
- 61 sites in United States, Canada and 3 more
- Volunteers
- 189 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis
While the repair of the epidermal barrier in atopic dermatitis is of major importance in the treatment of atopic dermatitis, most of the vehicles used may actually cause a worsening of an impaired epidermal barrier.
- Trial name
- NCT01065714
- Testing
- Hydrogel vehicle, Eucerin Lotion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Derm Research, PLLC
Soft Tissue Sarcoma
Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
Patients will receive neoadjuvant sorafenib (investigational agent) in combination with preoperative external beam conformal radiotherapy (50 Gy in 25 fractions) for localized, large soft tissue sarcomas of the extremity and body…
- Trial name
- NCT00864032
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Davis
Breast Cancer
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
Sorafenib is being looked at in a number of solid tumor settings including breast cancer. This trial is designed as a pilot study to assess the safety and tolerability of a novel oral agent in combination with standard…
- Trial name
- NCT00544167
- Testing
- Doxorubicin, Cyclophosphamide, Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 45 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer, CNS Disease
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer.
- Trial name
- NCT00496379
- Testing
- ZK219477
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nancy Lin, MD
Acne Vulgaris
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
The purpose of this study is to find out if taking a birth control pill, YAZ, is safe and effective for treating acne on the trunk (the main part of the body that does not include the arms, legs, and head).
- Trial name
- NCT00722761
- Testing
- drospirenone and ethinyl estradiol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Chronic Lymphocytic Leukemia
CFAR Study in Patients With Chronic Lymphocytic Leukemia
Primary Objective: 1. Evaluate the ability of Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) to increase the proportion of patients with <5% CD5/CD19+ cells in bone marrow to 66% following 3 courses of treatment…
- Trial name
- NCT00525603
- Testing
- Cyclophosphamide, Fludarabine, Alemtuzumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
This is a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. The initial patients on the dose-finding portion of this study will be enrolled through a single institution.
- Trial name
- NCT00536575
- Testing
- Bortezomib, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- SCRI Development Innovations, LLC
Dysmenorrhea
Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea
The purpose of this study is to investigate efficacy of ethinylestradiol for intracyclic bleeding profile in patients with dysmenorrhea and to investigate the long term safety
- Trial name
- NCT00461305
- Testing
- DRSP 3 mg/EE 20 µg (13 cycles), DRSP 3 mg/EE 30 µg (6 cycles)
- Where
- 26 sites in Japan
- Volunteers
- 420 people
- Sponsor
- Bayer
Macular Degeneration
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW1 (NCT00509795)
- Testing
- ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Where
- 188 sites in United States, Canada
- Volunteers
- 1,217 people
- Sponsor
- Regeneron Pharmaceuticals
Breast Cancer
Herceptin and GM-CSF for Metastatic Breast Cancer
Primary Objectives: 1. To determine the patient's tumor response rate that this protocol will produce. 2. To determine the 1 year progression-free survival that this protocol will produce. Secondary Objective: 1.
- Trial name
- NCT00429104
- Testing
- Herceptin, GM-CSF
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic…
- Trial name
- NCT00323557
- Testing
- Sargramostim (GM-CSF), Pneumococcal Vaccine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Coronary Syndrome
Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)
The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent acute coronary syndrome (ACS) and to assess the ability of rivaroxaban to reduce the occurrence of death, myocardial infarction (heart…
- Trial name
- NCT00402597
- Testing
- Rivaroxaban
- Volunteers
- 3,490 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acne Vulgaris, Post Inflammatory Hyperpigmentation
Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris.
- Trial name
- NCT01038869
- Testing
- Azelaic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Derm Research, PLLC